Spyre Therapeutics (SYRE) has released an update to notify the public and investors about an entry into a material definitive agreement.
Spyre Therapeutics, Inc. has introduced a new indemnification agreement for its board members and executive officers, replacing previous arrangements from its predecessor, Aeglea BioTherapeutics, Inc. This agreement assures these key personnel that the company will cover legal expenses and provide indemnity for their official actions, offering them protection as they manage and represent the company’s interests.
For further insights into SYRE stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
